ACADEMIA
Nearly 30% of RA Patients Show LDA 3 Years After Discontinuing Remicade: Prof. Tanaka of Univ. of Occupational and Environmental Health
Yoshiya Tanaka, professor of the Department of Internal Medicine (I), University of Occupational and Environmental Health, Japan, announced results from the domestic multi-center cooperative RRR (remission induction by Remicade in RA) study at a media briefing on the rheumatoid arthritis…
To read the full story
ACADEMIA
- Dementia Drugs See Modest Uptake in Japan amid Eligibility Limits, Safety Concerns
April 9, 2026
- Cancer Drug Supply Risks Spur Calls for Pricing Reform: JSMO
March 31, 2026
- Japan Ophthalmology Society Flags Off-Label Concerns Ahead of Upneeq Launch
March 30, 2026
- Real-World Study Backs Lecanemab Safety, 90% Stay on Treatment
March 25, 2026
- CAR-T Reimbursement Insufficient, Kyoto University Hospital Chief Warns
March 11, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





